AU729423B2 - Antithrombotic organic nitrates - Google Patents
Antithrombotic organic nitrates Download PDFInfo
- Publication number
- AU729423B2 AU729423B2 AU55519/98A AU5551998A AU729423B2 AU 729423 B2 AU729423 B2 AU 729423B2 AU 55519/98 A AU55519/98 A AU 55519/98A AU 5551998 A AU5551998 A AU 5551998A AU 729423 B2 AU729423 B2 AU 729423B2
- Authority
- AU
- Australia
- Prior art keywords
- compounds
- accordance
- integer
- chosen
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 12
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 11
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 229960004605 timolol Drugs 0.000 claims abstract description 21
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims abstract description 20
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 9
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 108010061435 Enalapril Proteins 0.000 claims description 18
- 229960000873 enalapril Drugs 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- -1 Qtiinapril Chemical compound 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 9
- 238000009739 binding Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229960004676 antithrombotic agent Drugs 0.000 claims description 3
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims description 3
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims description 2
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 claims description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 2
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 claims description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 2
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 2
- 229950007884 alacepril Drugs 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 claims description 2
- 229960004374 befunolol Drugs 0.000 claims description 2
- 229960004530 benazepril Drugs 0.000 claims description 2
- 229960004324 betaxolol Drugs 0.000 claims description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 2
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 claims description 2
- 229960000330 bupranolol Drugs 0.000 claims description 2
- 229960000830 captopril Drugs 0.000 claims description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960001222 carteolol Drugs 0.000 claims description 2
- 229950005749 ceronapril Drugs 0.000 claims description 2
- 229960005025 cilazapril Drugs 0.000 claims description 2
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 2
- 229960005227 delapril Drugs 0.000 claims description 2
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 2
- 229960002680 enalaprilat Drugs 0.000 claims description 2
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims description 2
- 229960002490 fosinopril Drugs 0.000 claims description 2
- 229960001195 imidapril Drugs 0.000 claims description 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 2
- 229960001632 labetalol Drugs 0.000 claims description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 2
- 229960000831 levobunolol Drugs 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 2
- 229960003134 mepindolol Drugs 0.000 claims description 2
- 229960002704 metipranolol Drugs 0.000 claims description 2
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004570 oxprenolol Drugs 0.000 claims description 2
- 229960002582 perindopril Drugs 0.000 claims description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
- 229960003401 ramipril Drugs 0.000 claims description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 2
- 229960002909 spirapril Drugs 0.000 claims description 2
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims description 2
- 108700035424 spirapril Proteins 0.000 claims description 2
- 229960004084 temocapril Drugs 0.000 claims description 2
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 claims description 2
- 229960002051 trandolapril Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000003293 cardioprotective effect Effects 0.000 claims 2
- 101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 claims 1
- 108010066671 Enalaprilat Proteins 0.000 claims 1
- 101100305983 Mus musculus Rom1 gene Proteins 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940045200 cardioprotective agent Drugs 0.000 claims 1
- 239000012659 cardioprotective agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000002483 medication Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 101710134784 Agnoprotein Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229940113083 morpholine Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 150000002828 nitro derivatives Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 206010006482 Bronchospasm Diseases 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000007885 bronchoconstriction Effects 0.000 description 4
- 229960002504 capsaicin Drugs 0.000 description 4
- 235000017663 capsaicin Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZAEPXWFVTMAFEH-UHFFFAOYSA-N (2-hydroxyphenyl)methyl nitrate Chemical compound OC1=CC=CC=C1CO[N+]([O-])=O ZAEPXWFVTMAFEH-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003435 bronchoconstrictive effect Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 description 1
- LRTRXDSAJLSRTG-UHFFFAOYSA-N 4-bromobutanoyl chloride Chemical compound ClC(=O)CCCBr LRTRXDSAJLSRTG-UHFFFAOYSA-N 0.000 description 1
- ZETOHPSSBWBMED-UHFFFAOYSA-N 4-nitrooxybutanoic acid Chemical compound OC(=O)CCCO[N+]([O-])=O ZETOHPSSBWBMED-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102100021587 Embryonic testis differentiation protein homolog A Human genes 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 101000898120 Homo sapiens Embryonic testis differentiation protein homolog A Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101100166829 Mus musculus Cenpk gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- HZUMMZVMNQSPFF-UHFFFAOYSA-N nitro butaneperoxoate Chemical compound CCCC(=O)OO[N+]([O-])=O HZUMMZVMNQSPFF-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C203/00—Esters of nitric or nitrous acid
- C07C203/02—Esters of nitric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI002368A IT1295694B1 (it) | 1996-11-14 | 1996-11-14 | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| ITMI96A002368 | 1996-11-14 | ||
| PCT/EP1997/006311 WO1998021193A1 (en) | 1996-11-14 | 1997-11-12 | Antithrombotic organic nitrates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5551998A AU5551998A (en) | 1998-06-03 |
| AU729423B2 true AU729423B2 (en) | 2001-02-01 |
Family
ID=11375213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU55519/98A Ceased AU729423B2 (en) | 1996-11-14 | 1997-11-12 | Antithrombotic organic nitrates |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6242432B1 (https=) |
| EP (1) | EP0941218B1 (https=) |
| JP (1) | JP4264137B2 (https=) |
| KR (1) | KR100504122B1 (https=) |
| CN (1) | CN1094931C (https=) |
| AT (1) | ATE226199T1 (https=) |
| AU (1) | AU729423B2 (https=) |
| BR (1) | BR9712959B1 (https=) |
| CA (1) | CA2272063C (https=) |
| DE (1) | DE69716461T2 (https=) |
| DK (1) | DK0941218T3 (https=) |
| ES (1) | ES2186013T3 (https=) |
| HU (1) | HUP0000667A3 (https=) |
| IL (1) | IL129768A (https=) |
| IT (1) | IT1295694B1 (https=) |
| PT (1) | PT941218E (https=) |
| RU (1) | RU2190594C2 (https=) |
| WO (1) | WO1998021193A1 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9801398D0 (en) | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
| IT1301759B1 (it) * | 1998-06-19 | 2000-07-07 | Nicox Sa | Sali nitrati di farmaci antiipertensivi |
| IT1311923B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| IE20000052A1 (en) * | 1999-04-29 | 2000-11-29 | Russinsky Ltd | Nitric acid salts of B-blockers |
| IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
| WO2001017528A1 (en) | 1999-09-08 | 2001-03-15 | Nitromed, Inc. | Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| US7537785B2 (en) * | 1999-10-29 | 2009-05-26 | Nitromed, Inc. | Composition for treating vascular diseases characterized by nitric oxide insufficiency |
| US7708989B2 (en) | 1999-10-29 | 2010-05-04 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US6635273B1 (en) | 1999-10-29 | 2003-10-21 | Trustees Of Boston University | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US7235237B2 (en) | 1999-10-29 | 2007-06-26 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| AP2002002582A0 (en) * | 1999-12-23 | 2002-09-30 | Nitromed Inc | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| ATE412774T1 (de) | 2000-02-16 | 2008-11-15 | Illumina Inc | Parallele genotypisierung mehrerer patientenproben |
| CA2410632A1 (en) | 2000-06-22 | 2001-12-27 | David S. Garvey | Nitrosated and nitrosylated taxanes, compositions and methods of use |
| EP1337283A4 (en) * | 2000-10-27 | 2005-05-18 | Nitromed Inc | METHOD FOR THE TREATMENT OF VASCULAR DISORDERS MARKED BY STICK OXIDE DEFICIENCY |
| EP1219306A1 (en) * | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| WO2002087508A2 (en) | 2001-05-02 | 2002-11-07 | Nitromed, Inc. | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| GB0111872D0 (en) * | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
| US7968605B2 (en) * | 2002-02-04 | 2011-06-28 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
| NZ534912A (en) * | 2002-02-04 | 2007-08-31 | Alfama Investigacao E Desenvol | supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative |
| US20080026984A1 (en) * | 2002-02-04 | 2008-01-31 | Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
| AU2003215240A1 (en) | 2002-02-14 | 2003-09-04 | Illumina, Inc. | Automated information processing in randomly ordered arrays |
| CA2487414A1 (en) | 2002-06-11 | 2003-12-18 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| EP1562975A2 (en) * | 2002-10-25 | 2005-08-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
| GB2395432B (en) * | 2002-11-20 | 2005-09-14 | Northwick Park Inst For Medica | Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs |
| US20060258652A1 (en) * | 2002-11-22 | 2006-11-16 | Haj-Yehia Abdullah I | Beta-blockers having antioxidant and no-donor activity |
| US20060166894A1 (en) * | 2002-11-29 | 2006-07-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ace-inhibitors having antioxidant and no-donor activity |
| US20070207217A1 (en) * | 2003-02-03 | 2007-09-06 | Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda | Method for treating a mammal by administration of a compound having the ability to release CO |
| US7166638B2 (en) | 2003-05-27 | 2007-01-23 | Nicox S.A. | Statin derivatives |
| US7169805B2 (en) * | 2003-05-28 | 2007-01-30 | Nicox S.A. | Captopril derivatives |
| AU2004246821A1 (en) * | 2003-06-19 | 2004-12-23 | Nicox S.A. | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases |
| JP2007502831A (ja) * | 2003-08-20 | 2007-02-15 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法 |
| HRP20070283T3 (en) | 2003-12-02 | 2007-11-30 | Nicox S.A. | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive drugs |
| AR047264A1 (es) * | 2003-12-02 | 2006-01-11 | Nicox Sa | Nitrooxiderivados de drogas antihipertensivas |
| BRPI0418245B8 (pt) | 2004-01-05 | 2021-05-25 | Nicox Sa | composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes |
| EP1778267A4 (en) * | 2004-07-16 | 2010-01-06 | Nitromed Inc | COMPOSITIONS AND METHODS RELATED TO HEART ERROR |
| ATE462703T1 (de) | 2004-08-25 | 2010-04-15 | Actelion Pharmaceuticals Ltd | Bicyclononen-derivate als renin-inhibitoren |
| CA2576279A1 (en) * | 2004-11-08 | 2006-05-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
| AU2006206249A1 (en) * | 2005-01-21 | 2006-07-27 | Nicox S.A. | Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| GEP20115206B (en) * | 2005-05-27 | 2011-04-26 | Actelion Pharmaceuticals Ltd | Novel piperidine carboxylic acid amide derivatives |
| EP1899295A2 (en) * | 2005-06-29 | 2008-03-19 | Pfizer, Inc. | Prostaglandin derivatives |
| WO2007045551A2 (en) * | 2005-10-18 | 2007-04-26 | Nicox S.A. | Renin inhibitors nitroderivatives |
| GB0601394D0 (en) | 2006-01-24 | 2006-03-01 | Hemocorm Ltd | Therapeutic delivery of carbon monoxide |
| NZ570828A (en) | 2006-02-02 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Secondary amines as renin inhibitors |
| AU2007217980A1 (en) * | 2006-02-17 | 2007-08-30 | Nitromed, Inc. | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| CN101395149A (zh) * | 2006-03-08 | 2009-03-25 | 埃科特莱茵药品有限公司 | 新颖胺类 |
| JP2007275193A (ja) * | 2006-04-04 | 2007-10-25 | Fujifilm Corp | 光プローブおよび光断層画像化装置 |
| EP2024337A4 (en) * | 2006-05-16 | 2011-09-14 | Nitromed Inc | SOLID DOSAGE FORMULATIONS OF HYDRALAZIN COMPOUNDS |
| RU2322972C1 (ru) * | 2006-09-12 | 2008-04-27 | Илья Николаевич Медведев | Способ профилактики тромбозов у больных артериальной гипертонией с метаболическим синдромом |
| TW200831079A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Angiotensin II receptor antagonists |
| FR2921365B1 (fr) * | 2007-09-21 | 2012-10-12 | Servier Lab | Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| KR101403311B1 (ko) * | 2008-05-05 | 2014-06-05 | 액테리온 파마슈티칼 리미티드 | 레닌 억제제로서의 3,4-치환된 피페리딘 유도체 |
| WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| WO2011160974A2 (en) | 2010-06-21 | 2011-12-29 | Nicox S.A. | Statin derivatives |
| EP2699242B1 (en) | 2011-04-19 | 2017-11-01 | Alfama, Inc. | Carbon monoxide releasing molecules and uses thereof |
| JP6134710B2 (ja) | 2011-07-21 | 2017-05-24 | アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． | 一酸化ルテニウム放出分子およびその使用 |
| CA2897571C (en) | 2013-01-21 | 2018-12-18 | Apparao Satyam | Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group |
| US11058691B2 (en) | 2016-11-08 | 2021-07-13 | Nicox S.A. | Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma |
| RS66218B1 (sr) | 2019-07-01 | 2024-12-31 | Tonix Pharma Ltd | Anti-cd154 antitela i njihove upotrebe |
| WO2022150452A1 (en) | 2021-01-06 | 2022-07-14 | Seth Lederman | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| CN118146175A (zh) * | 2024-02-07 | 2024-06-07 | 广州楷石生物科技有限公司 | 右旋噻吗洛尔衍生物及其制备方法和应用 |
| WO2025248134A1 (en) | 2024-05-31 | 2025-12-04 | Tonix Pharma Limited | Treatment methods comprising administration of modified cd154 antibodies |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0637583A1 (en) * | 1993-07-30 | 1995-02-08 | Prodesfarma, S.A. | 1-Aryloxy-3-alkylamino-2-propanol nitrate esters, the use thereof and corresponding pharmaceutical composition |
| WO1995030641A1 (en) * | 1994-05-10 | 1995-11-16 | Nicox S.A. | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| AU2230897A (en) * | 1996-03-01 | 1997-09-16 | Sankyo Company Limited | Thiazolidine derivatives |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1256345B (it) | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| IT1256450B (it) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| EP0722434B1 (en) | 1993-10-06 | 1998-07-29 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation |
-
1996
- 1996-11-14 IT IT96MI002368A patent/IT1295694B1/it active IP Right Grant
-
1997
- 1997-11-12 WO PCT/EP1997/006311 patent/WO1998021193A1/en not_active Ceased
- 1997-11-12 AU AU55519/98A patent/AU729423B2/en not_active Ceased
- 1997-11-12 BR BRPI9712959-3A patent/BR9712959B1/pt not_active IP Right Cessation
- 1997-11-12 HU HU0000667A patent/HUP0000667A3/hu unknown
- 1997-11-12 DK DK97951890T patent/DK0941218T3/da active
- 1997-11-12 IL IL12976897A patent/IL129768A/en not_active IP Right Cessation
- 1997-11-12 CN CN97181245A patent/CN1094931C/zh not_active Expired - Fee Related
- 1997-11-12 AT AT97951890T patent/ATE226199T1/de active
- 1997-11-12 KR KR10-1999-7004229A patent/KR100504122B1/ko not_active Expired - Fee Related
- 1997-11-12 JP JP52217998A patent/JP4264137B2/ja not_active Expired - Fee Related
- 1997-11-12 US US09/297,933 patent/US6242432B1/en not_active Expired - Fee Related
- 1997-11-12 DE DE69716461T patent/DE69716461T2/de not_active Expired - Lifetime
- 1997-11-12 RU RU99112517/04A patent/RU2190594C2/ru not_active IP Right Cessation
- 1997-11-12 EP EP97951890A patent/EP0941218B1/en not_active Expired - Lifetime
- 1997-11-12 ES ES97951890T patent/ES2186013T3/es not_active Expired - Lifetime
- 1997-11-12 CA CA002272063A patent/CA2272063C/en not_active Expired - Fee Related
- 1997-11-12 PT PT97951890T patent/PT941218E/pt unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0637583A1 (en) * | 1993-07-30 | 1995-02-08 | Prodesfarma, S.A. | 1-Aryloxy-3-alkylamino-2-propanol nitrate esters, the use thereof and corresponding pharmaceutical composition |
| WO1995030641A1 (en) * | 1994-05-10 | 1995-11-16 | Nicox S.A. | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| AU2230897A (en) * | 1996-03-01 | 1997-09-16 | Sankyo Company Limited | Thiazolidine derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998021193A1 (en) | 1998-05-22 |
| CN1242768A (zh) | 2000-01-26 |
| HUP0000667A3 (en) | 2000-08-28 |
| BR9712959A (pt) | 2000-02-01 |
| IL129768A0 (en) | 2000-02-29 |
| KR100504122B1 (ko) | 2005-07-27 |
| DK0941218T3 (da) | 2003-02-17 |
| ES2186013T3 (es) | 2003-05-01 |
| ITMI962368A0 (it) | 1996-11-14 |
| CA2272063C (en) | 2008-05-27 |
| DE69716461T2 (de) | 2003-06-26 |
| ITMI962368A1 (it) | 1998-05-14 |
| AU5551998A (en) | 1998-06-03 |
| IT1295694B1 (it) | 1999-05-27 |
| PT941218E (pt) | 2003-03-31 |
| JP2001507676A (ja) | 2001-06-12 |
| IL129768A (en) | 2004-02-19 |
| HUP0000667A2 (en) | 2000-07-28 |
| CN1094931C (zh) | 2002-11-27 |
| RU2190594C2 (ru) | 2002-10-10 |
| BR9712959B1 (pt) | 2010-06-01 |
| CA2272063A1 (en) | 1998-05-22 |
| EP0941218A1 (en) | 1999-09-15 |
| KR20000053251A (ko) | 2000-08-25 |
| JP4264137B2 (ja) | 2009-05-13 |
| DE69716461D1 (de) | 2002-11-21 |
| US6242432B1 (en) | 2001-06-05 |
| ATE226199T1 (de) | 2002-11-15 |
| EP0941218B1 (en) | 2002-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU729423B2 (en) | Antithrombotic organic nitrates | |
| US4443475A (en) | Amides of acyl-carnitines, process for preparing same and pharmaceutical compositions containing such amides | |
| PT101027A (pt) | Peptideos, processo para a sua preparacao e sua utilizacao como compostos farmaceuticos | |
| RU2092492C1 (ru) | Производные гидразина или их соли, фармацевтическое средство, аминоалкилгидразины или их соли | |
| JPH01160992A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| IE63903B1 (en) | Perhydrothiazepine derivatives their preparation and their therapeutic use | |
| CA2157187A1 (en) | Novel distamycin analogues | |
| HU211266A9 (en) | New peptide compound and a process for the preparation thereof | |
| CA2092414A1 (en) | N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors | |
| JPS60136595A (ja) | 置換エチレンジアミン誘導体、その製造方法及び該誘導体を含む医薬製剤 | |
| JPH05507295A (ja) | Ｎ―（α―置換―ピリジニル）カルボニルジペプチド抗高血圧剤 | |
| EP1635816B1 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
| US4420490A (en) | Substituted phenylacetic acid amide compounds | |
| IE68060B1 (en) | Nitratoalkanecarboxylic acid derivatives a process for their preparation use thereof and medicaments containing them | |
| KR890000769B1 (ko) | 프롤린 유도체의 제법 | |
| IT8009577A1 (it) | Nuovi derivati 1-oxadetiacefalosporina, loro produzione, e loro impiego come antibatterici | |
| US4354966A (en) | Peptides, process for preparation thereof and use thereof | |
| JPS595578B2 (ja) | ペプチドの製造方法 | |
| US3951957A (en) | Chloromethyl ester of penicillins | |
| IE65539B1 (en) | Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same | |
| KR890000770B1 (ko) | 프롤린 유도체의 제법 | |
| IL45776A (en) | Thiamphenicol derivatives their manufacture and pharmaceutical compositions containing them | |
| ITMI940696A1 (it) | Derivati dell'acido fosfonico utili nel trattamento delle malattie car. iovascolari | |
| JPS58131968A (ja) | チオ−ルエステル化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |